A5065215252- Cancer Research and Treatments
- HER2/EGFR in Cancer Research
- Nanoplatforms for cancer theranostics
- Monoclonal and Polyclonal Antibodies Research
- Nanoparticle-Based Drug Delivery
- Extracellular vesicles in disease
- Cancer Immunotherapy and Biomarkers
- RNA Interference and Gene Delivery
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Advanced biosensing and bioanalysis techniques
- Viral Infectious Diseases and Gene Expression in Insects
- Immunotherapy and Immune Responses
- MicroRNA in disease regulation
- CAR-T cell therapy research
- Virus-based gene therapy research
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- bioluminescence and chemiluminescence research
- Photoreceptor and optogenetics research
- Phagocytosis and Immune Regulation
- Microbial Metabolic Engineering and Bioproduction
- Cancer Cells and Metastasis
- Mitochondrial Function and Pathology
- Galectins and Cancer Biology
The Ohio State University
2024
University of Alabama at Birmingham
2018-2024
Exosomes hold great potential to deliver therapeutic reagents for cancer treatment due its inherent low antigenicity. However, several technical barriers, such as productivity and ineffective targeting, need be overcome before wide clinical applications. The present study aims at creating a new biomanufacturing platform of cancer-targeted exosomes drug delivery. Specifically, scalable, robust, high-yield, cell line based exosome production process is created in stirred-tank bioreactor, an...
Adeno-associated viruses (AAVs) have been well characterized and used to deliver therapeutic genes for diseases treatment in clinics basic research. This study the triple transient transfection of AAV-DJ/8 as a model expression system develop optimize laboratory production AAV research pre-clinical applications. Specifically, various parameters, including host cell, reagent, cell density, ratio plasmid DNA cells, gene size, mode, were tested determine optimal process. Our results showed that...
Abstract Triple‐negative breast cancers (TNBCs) are highly aggressive, metastatic and recurrent. Cytotoxic chemotherapies with limited clinical benefits severe side effects the standard therapeutic strategies, but, to date, there is no efficacious targeted therapy. Literature our data showed that epidermal growth factor receptor (EGFR) overexpressed on TNBC cell surface a promising oncological target. The objective of this study was develop an antibody‐drug conjugate (ADC) target EGFR +...
Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous disease that often relapses following treatment with standard radiotherapies cytotoxic chemotherapies. Combination therapies have potential for treating refractory metastatic TNBC. In this study, we aimed to develop an antibody-drug conjugate dual payloads (DualADC) as chemoimmunotherapy The overexpression of immune checkpoint transmembrane CD276 (also known B7-H3) was associated angiogenesis, metastasis, tolerance...
Antibody-drug conjugate (ADC) is a class of targeted cancer therapies that combine the advantages monoclonal antibody (mAb)'s specific targeting and chemotherapy's potent cytotoxicity. The therapeutic effect ADC significantly affected by its bioproduction process. This study aims to develop an effective production process using anti-HER2 mAb-drug as model therapeutic. First, high titer (>2 g/L) mAb was produced Chinese hamster ovary cells from fed-batch cell culture. Both live-cell confocal...
Triple-negative breast cancers (TNBCs) are frequently recurrent due to the development of drug resistance post chemotherapy. Both existing literature and our study found that surface receptor CD47 (cluster differentiation 47) was upregulated in chemotherapy-treated TNBC cells. The goal this develop a monoclonal antibody (mAb)-based targeting strategy treat after standard treatment. Specifically, new mAb targets extracellular domain developed using hybridoma technology produced fed-batch...
Glioblastomas, accounting for approximately 50% of gliomas, comprise the most aggressive, highly heterogeneous, and malignant brain tumors. The objective this study was to develop evaluate a new targeted therapy, i.e., potent natural compound verrucarin A (Ver-A), delivered with monoclonal antibody-directed extracellular vesicle (mAb-EV). First, high surface expression epidermal growth factor receptor (EGFR) in glioblastoma patient tissue cell lines confirmed using immunohistochemistry...
Triple-negative breast cancers (TNBCs) are highly aggressive and recurrent. Standard cytotoxic chemotherapies currently the main treatment options, but their clinical efficacies limited patients usually suffer from severe side effects. The goal of this study was to develop evaluate targeted liposomes-delivered combined treat TNBCs. Specifically, IC50 values microtubule polymerization inhibitor mertansine (DM1), mitotic spindle assembly defecting taxane (paclitaxel, PTX), DNA synthesis...
Triple-negative breast cancers (TNBCs) are heterogeneous and metastatic, targeted therapy is highly needed for TNBC treatment. Recent studies showed that extracellular vesicles (EV) have great potential to deliver therapies treat cancers. This study aimed develop evaluate a natural compound, verrucarin A (Ver-A), delivered by EV, TNBC. First, the surface expression of epidermal growth factor receptor (EGFR) CD47 were confirmed with immunohistochemistry (IHC) staining patient tissue...
Neuroendocrine (NE) cancers arise from cells within the neuroendocrine system. Chemotherapies and endoradiotherapy have been developed, but their clinical efficacy is limited. The objective of this study was to develop a dual-targeted extracellular vesicles (EV)-delivered combined therapies treat NE cancer. Specifically, we produced EV in stirred-tank bioreactors surface tagged both anti-somatostatin receptor 2 (SSTR 2) monoclonal antibody (mAb) anti-C-X-C motif chemokine 4 (CXCR4) mAb...
The adoptive transfer of human T cells or genetically-engineered with cancer-targeting receptors has shown tremendous promise for eradicating tumors in clinical trials. objective this study was to develop a novel cell biomanufacturing platform using stirred-tank bioreactor large-scale and high-quality cellular production. First, various factors, such as parameters, media, supplements, stimulation, seed age, donors, were investigated. A serum-free fed-batch bioproduction process developed...
Abstract Targeting cancer cell mitochondria holds great therapeutic promise, yet current strategies to specifically and effectively destroy in vivo are limited. Here, we introduce mLumiOpto, an innovative mitochondrial-targeted luminoptogenetics gene therapy designed directly disrupt the inner mitochondrial membrane (IMM) potential induce death. We synthesize a blue light-gated channelrhodopsin (CoChR) IMM co-express bioluminescence-emitting Nanoluciferase (NLuc) cytosol of same cells. The...
Abstract Mitochondria are important in various aspects of cancer development and progression. Targeting mitochondria cells holds great therapeutic promise, yet current strategies to specifically effectively destroy vivo limited. Here, we developed mLumiOpto, an innovative mitochondrial-targeted luminoptogenetics gene therapy designed directly disrupt the inner mitochondrial membrane (IMM) potential induce cell death. The approach included synthesis a blue light-gated cationic...
<div>Abstract<p>Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous disease that often relapses following treatment with standard radiotherapies cytotoxic chemotherapies. Combination therapies have potential for treating refractory metastatic TNBC. In this study, we aimed to develop an antibody–drug conjugate dual payloads (DualADC) as chemoimmunotherapy The overexpression of immune checkpoint transmembrane CD276 (also known B7-H3) was associated...
Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there no effective targeted therapy approved to control meningiomas. This study aimed develop and evaluate an anti-SSTR2 antibody–drug conjugate (ADC) target treat The meningioma targeting, circulation stability, toxicity, anti-tumor efficacy SSTR2 ADC were evaluated using cell lines and/or intracranial...
Abstract Neuroendocrine (NE) cancers include a diverse spectrum of hormone-secreting neoplasms that arise from the endocrine and nervous systems. Current chemo- radio- therapies have marginal curative benefits. This study aimed to develop an innovative antibody-drug conjugate (ADC) effectively treat NE tumors (NETs). We first confirmed somatostatin receptor 2 (SSTR2) is ideal surface target by analyzing 38 patient-derived NET tissues, 33 normal organs, 3 cell lines. then developed new...
<p>Supplementary Figure S3</p>
<p>Supplementary Figure S6</p>
<p>Supplementary Figure S7</p>
<p>Supplementary Figure S4</p>